Micrologix biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry G. who wrote (672)	2/18/2000 4:29:00 AM
From: Graham Dellaire	Read Replies (1) of 792

The spectre of production of peptides in large enough quantities for internal/intravenous use will probably seriously delay any internal drug. Topical drugs are a great way to use the MBI peptides before they figure out how to really ramp up production. Serious competition will come from small molecule drugs created by the pharmas... it makes sense now why no pharma has co-ventured with MBI. They have their own stable of products and they are shying away from the peptide sythesis/scale-up problems. Good news on the ability of MBI to do large scale manufacture of the peptides will be the best news of all! Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next